Client had recently acquired a CRO focusing on Phase 1-3 clinical trials for Pharma and Biotech customers. They were keen to augment the portfolio company’s capabilities by acquiring complementary assets in the US and also to broaden the services offering
Our approach
We leveraged our IP to generate a comprehensive database of CROs offering services that could be considered complementary to the portfolio company. Based on our research, we identified, evaluated and prioritized over 200 add-on targets and initiated contact with selected potential targets.
Results
Our client (mid-market private equity fund), managed to close 2 add-on deals for their CRO portfolio company, within a period of one year.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
